{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T17:06:14Z","timestamp":1779728774203,"version":"3.53.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10147-026-03021-2","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T10:21:30Z","timestamp":1775730090000},"page":"929-930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma"],"prefix":"10.1007","volume":"31","author":[{"given":"Noriomi","family":"Matsumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"3021_CR1","unstructured":"Pharmaceuticals and Medical Devices Agency (2026) List of approved drugs (in Japanese). https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/review-information\/p-drugs\/0010.html Accessed on 24 Mar 2026"},{"key":"3021_CR2","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1200\/JCO.23.02626","volume":"42","author":"M Yagisawa","year":"2024","unstructured":"Yagisawa M, Taniguchi H, Satoh T et al (2024) Trastuzumab deruxtecan in advanced solid tumors with human epidermal growth factor receptor 2 amplification identified by plasma cell-free DNA testing: a multicenter, single-arm, phase II basket trial. J Clin Oncol 42:3817\u20133825. https:\/\/doi.org\/10.1200\/JCO.23.02626","journal-title":"J Clin Oncol"},{"key":"3021_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A et al (2024) Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 42:47\u201358. https:\/\/doi.org\/10.1200\/JCO.23.02005","journal-title":"J Clin Oncol"},{"key":"3021_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","volume":"25","author":"K Raghav","year":"2024","unstructured":"Raghav K, Siena S, Takashima A et al (2024) Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol 25:1147\u20131162. https:\/\/doi.org\/10.1016\/S1470-2045(24)00380-2","journal-title":"Lancet Oncol"},{"key":"3021_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","volume":"25","author":"EF Smit","year":"2024","unstructured":"Smit EF, Felip E, Uprety D et al (2024) Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol 25:439\u2013454. https:\/\/doi.org\/10.1016\/S1470-2045(24)00064-0","journal-title":"Lancet Oncol"},{"key":"3021_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(25)00684-1","volume":"406","author":"N Agarwal","year":"2025","unstructured":"Agarwal N, Fizazi K, Matsubara N et al (2025) Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet 406:449\u2013460. https:\/\/doi.org\/10.1016\/S0140-6736(25)00684-1","journal-title":"Lancet"},{"key":"3021_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","volume":"406","author":"K Fizazi","year":"2025","unstructured":"Fizazi K, Azad AA, Matsubara N et al (2025) Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet 406:461\u2013473","journal-title":"Lancet"},{"key":"3021_CR8","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F et al (2023) Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 402:1423\u20131433. https:\/\/doi.org\/10.1016\/S0140-6736(23)01245-X","journal-title":"Lancet"},{"key":"3021_CR9","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1007\/s10147-024-02589-x","volume":"29","author":"Y Naito","year":"2024","unstructured":"Naito Y, Nakamura S, Kawaguchi-Sakita N et al (2024) Preliminary results from ASCENT-J02: a phase 1\/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors. Int J Clin Oncol 29:1684\u20131695. https:\/\/doi.org\/10.1007\/s10147-024-02589-x","journal-title":"Int J Clin Oncol"},{"issue":"16_suppl","key":"3021_CR10","doi-asserted-by":"publisher","first-page":"6007","DOI":"10.1200\/JCO.2025.43.16_suppl.6007","volume":"43","author":"S Okano","year":"2025","unstructured":"Okano S, Tahara M, Tsukahara K et al (2025) Darolutamide plus goserelin for androgen receptor-positive salivary gland cancers: Results of phase 2 study (DISCOVARY). J Clin Oncol 43(16_suppl):6007. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.6007","journal-title":"J Clin Oncol"},{"issue":"11 Suppl 1","key":"3021_CR11","doi-asserted-by":"publisher","first-page":"102737","DOI":"10.1016\/j.ijgc.2025.102737","volume":"35","author":"X Wu","year":"2025","unstructured":"Wu X, Yonemori K, Niimi K et al (2025) Global phase II study of risovalisib, a selective PI3K\u03b1 inhibitor, as monotherapy in patients with recurrent\/persistent ovarian clear cell carcinoma harboring PIK3CA hotspot mutations. Int J Gynecol Cancer 35(11 Suppl 1):102737. https:\/\/doi.org\/10.1016\/j.ijgc.2025.102737","journal-title":"Int J Gynecol Cancer"},{"key":"3021_CR12","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1200\/JCO-25-01957","volume":"43","author":"LE Budde","year":"2025","unstructured":"Budde LE, Zhang H, Kim WS et al (2025) Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory\/relapsed large B-cell lymphoma: primary results of the phase III SUNMO trial. J Clin Oncol 43:3799\u20133811. https:\/\/doi.org\/10.1200\/JCO-25-01957","journal-title":"J Clin Oncol"},{"key":"3021_CR13","unstructured":"Pharmaceuticals and Medical Devices Agency (2026) Revisions of PRECAUTIONS (FY2025). https:\/\/www.pmda.go.jp\/english\/safety\/info-services\/drugs\/revision-of-precautions\/0013.html Accessed on 24 Mar 2026"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03021-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03021-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03021-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:53:05Z","timestamp":1779727985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03021-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3021"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03021-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"9 April 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No author has any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}